NeuroBo Pharmaceuticals, Inc. (Nasdaq:NRBO) is a clinical-stage biopharmaceutical company that develops therapies for neurodegenerative diseases. Its lead product candidate is designed to treat patients with diabetic neuropathy, a common complication of diabetes that causes nerve damage and can lead to severe pain and other symptoms. Ultimately, the company seeks to develop innovative treatments that address significant unmet medical needs.
Comps: Finch Therapeutics Group, Inc. (Nasdaq:FNCH), GeoVax Labs, Inc. (Nasdaq:GOVX)
Before we compare, it is important to point out that these companies currently do not have a positive cash flow. With that being said, NeuroBo Pharmaceuticals stands out in several key areas compared to its competitors. Specifically, it has a higher profit margin and return-on-equity, which indicate better financial efficiency and performance. Furthermore, its net income is more favorable than that of Finch Therapeutics Group.